• Outcome of Annual General meeting of june 2, 2016

    June 3, 2016
    Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces the results of the voting by shareholders at the Annual General Meeting (“AGM”) which took place on June 2, 2016, in Marseille, France...
  • Investor & Analyst Update, New York, May 16th, 2016

    May 16, 2016
    Update on strategy and pipeline Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and...
  • First quarter 2016 report

    May 4, 2016
    Cash, cash equivalents and financial instruments of the Company amounted to €255.8 million ; Broad innovative pipeline including three clinical-stage programs; expect first clinical data in 2016; Two...
  • Upcoming investor conferences

    April 28, 2016
    Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that it will be present at the following investor events during the second quarter of 2016: Gilbert Dupont...